Biotechnology And Society
Download Biotechnology And Society full books in PDF, epub, and Kindle. Read online free Biotechnology And Society ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Author | : Daniel Lee Kleiman |
Publisher | : John Wiley & Sons |
Total Pages | : 160 |
Release | : 2009-02-09 |
Genre | : Social Science |
ISBN | : 1405148195 |
This thoughtful and engaging text challenges the widely held notion of science as somehow outside of society, and the idea that technology proceeds automatically down a singular and inevitable path. Through specific case studies involving contemporary debates, this book shows that science and technology are fundamentally part of society and are shaped by it. Draws on concepts from political sociology, organizational analysis, and contemporary social theory. Avoids dense theoretical debate. Includes case studies and concluding chapter summaries for students and scholars.
Author | : John M. Walker |
Publisher | : |
Total Pages | : 458 |
Release | : 1988 |
Genre | : Biotechnology |
ISBN | : 9780851864532 |
A study of recent developments in molecular biology and biotechnology, including enzyme technology, genetics and various applications, for example in fermentation technology, protein technology, genetic engineering and product recovery.
Author | : Toby Freedman |
Publisher | : CSHL Press |
Total Pages | : 408 |
Release | : 2008 |
Genre | : Biotechnology |
ISBN | : 0879697253 |
An essential guide for students in the life sciences, established researchers, and career counselors, this resource features discussions of job security, future trends, and potential career paths. Even those already working in the industry will find helpful information on how to take advantage of opportunities within their own companies and elsewhere.
Author | : |
Publisher | : John Wiley & Sons |
Total Pages | : 744 |
Release | : 2013-12-16 |
Genre | : Science |
ISBN | : 111817979X |
Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs, Second Edition addresses the pivotal issues relating to translational science, including preclinical and clinical drug development, regulatory science, pharmaco-economics and cost-effectiveness considerations. The new edition also provides an update on new proteins and genetic medicines, the translational and integrated sciences that continue to fuel the innovations in medicine, as well as the new areas of therapeutic development including cancer vaccines, stem cell therapeutics, and cell-based therapies.
Author | : Arnold Thackray |
Publisher | : University of Pennsylvania Press |
Total Pages | : 288 |
Release | : 1998-01-29 |
Genre | : Science |
ISBN | : 9780812234282 |
Private Science is a contribution to that debate, focusing particularly on the relationships among corporations, universities, and national governments involved in biotechnological research.
Author | : Melinda E. Cooper |
Publisher | : University of Washington Press |
Total Pages | : 233 |
Release | : 2011-02-01 |
Genre | : Science |
ISBN | : 0295990317 |
Focusing on the period between the 1970s and the present, Life as Surplus is a pointed and important study of the relationship between politics, economics, science, and cultural values in the United States today. Melinda Cooper demonstrates that the history of biotechnology cannot be understood without taking into account the simultaneous rise of neoliberalism as a political force and an economic policy. From the development of recombinant DNA technology in the 1970s to the second Bush administration's policies on stem cell research, Cooper connects the utopian polemic of free-market capitalism with growing internal contradictions of the commercialized life sciences. The biotech revolution relocated economic production at the genetic, microbial, and cellular level. Taking as her point of departure the assumption that life has been drawn into the circuits of value creation, Cooper underscores the relations between scientific, economic, political, and social practices. In penetrating analyses of Reagan-era science policy, the militarization of the life sciences, HIV politics, pharmaceutical imperialism, tissue engineering, stem cell science, and the pro-life movement, the author examines the speculative impulses that have animated the growth of the bioeconomy. At the very core of the new post-industrial economy is the transformation of biological life into surplus value. Life as Surplus offers a clear assessment of both the transformative, therapeutic dimensions of the contemporary life sciences and the violence, obligation, and debt servitude crystallizing around the emerging bioeconomy.
Author | : George Estreich |
Publisher | : MIT Press |
Total Pages | : 239 |
Release | : 2019-03-19 |
Genre | : Science |
ISBN | : 0262351803 |
How new biomedical technologies—from prenatal testing to gene-editing techniques—require us to imagine who counts as human and what it means to belong. From next-generation prenatal tests, to virtual children, to the genome-editing tool CRISPR-Cas9, new biotechnologies grant us unprecedented power to predict and shape future people. That power implies a question about belonging: which people, which variations, will we welcome? How will we square new biotech advances with the real but fragile gains for people with disabilities—especially when their voices are all but absent from the conversation? This book explores that conversation, the troubled territory where biotechnology and disability meet. In it, George Estreich—an award-winning poet and memoirist, and the father of a young woman with Down syndrome—delves into popular representations of cutting-edge biotech: websites advertising next-generation prenatal tests, feature articles on “three-parent IVF,” a scientist's memoir of constructing a semisynthetic cell, and more. As Estreich shows, each new application of biotechnology is accompanied by a persuasive story, one that minimizes downsides and promises enormous benefits. In this story, people with disabilities are both invisible and essential: a key promise of new technologies is that disability will be repaired or prevented. In chapters that blend personal narrative and scholarship, Estreich restores disability to our narratives of technology. He also considers broader themes: the place of people with disabilities in a world built for the able; the echoes of eugenic history in the genomic present; and the equation of intellect and human value. Examining the stories we tell ourselves, the fables already creating our futures, Estreich argues that, given biotech that can select and shape who we are, we need to imagine, as broadly as possible, what it means to belong.
Author | : Sean D. Sutton |
Publisher | : State University of New York Press |
Total Pages | : 211 |
Release | : 2009-07-02 |
Genre | : Science |
ISBN | : 1438426607 |
Considers the ethics and challenges of biotechnology.
Author | : C. Ben Mitchell |
Publisher | : Georgetown University Press |
Total Pages | : 228 |
Release | : 2007-04-23 |
Genre | : Medical |
ISBN | : 9781589012769 |
Some of humankind's greatest tools have been forged in the research laboratory. Who could argue that medical advances like antibiotics, blood transfusions, and pacemakers have not improved the quality of people's lives? But with each new technological breakthrough there comes an array of consequences, at once predicted and unpredictable, beneficial and hazardous. Outcry over recent developments in the reproductive and genetic sciences has revealed deep fissures in society's perception of biotechnical progress. Many are concerned that reckless technological development, driven by consumerist impulses and greedy entrepreneurialism, has the potential to radically shift the human condition—and not for the greater good. Biotechnology and the Human Good builds a case for a stewardship deeply rooted in Judeo-Christian theism to responsibly interpret and assess new technologies in a way that answers this concern. The authors jointly recognize humans not as autonomous beings but as ones accountable to each other, to the world they live in, and to God. They argue that to question and critique how fields like cybernetics, nanotechnology, and genetics might affect our future is not anti-science, anti-industry, or anti-progress, but rather a way to promote human flourishing, common sense, and good stewardship. A synthetic work drawing on the thought of a physician, ethicists, and a theologian, Biotechnology and the Human Good reminds us that although technology is a powerful and often awe-inspiring tool, it is what lies in the heart and soul of who wields this tool that truly makes the difference in our world.
Author | : Donald L. Drakeman |
Publisher | : Oxford University Press |
Total Pages | : 241 |
Release | : 2022 |
Genre | : Biotechnology industries |
ISBN | : 0195084004 |
"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--